New medication helps heart health in people with chronic kidney disease, Type 2 diabetes

November 17, 2020

DALLAS, Nov. 16, 2020 -- The investigational medication finerenone reduced the risk of heart attack, stroke, heart failure and other negative cardiovascular events in patients with chronic kidney disease and Type 2 diabetes, according to late-breaking research presented today at the American Heart Association's Scientific Sessions 2020. The virtual meeting is Friday, November 13-Tuesday, November 17, 2020, and is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science for health care worldwide. The manuscript of this study is simultaneously published today in Circulation, journal of the American Heart Association.

In the largest trial of its kind to-date, the study, "Finerenone and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes" (FIDELIO-DKD), found that finerenone reduced the risk of cardiac events for patients regardless of whether they had a history of heart disease or not. Finerenone - a novel, nonsteroidal, selective mineralocorticoid receptor antagonist - reduced both the risk of worsening kidney disease and risk of death related to heart problems.

"We are pleased to see that finerenone could provide a meaningful treatment option for patients who are battling chronic conditions," said Gerasimos Filippatos, M.D., the study's lead author and a professor of cardiology at the National and Kapodistrian University of Athens in Greece.

The FIDELIO-DKD study is a phase III, randomized, double-blind, placebo-controlled trial that enrolled nearly 6,000 patients (average age 66; 70.2% male) at more than 900 sites in 48 countries. The goal was to investigate finerenone in patients with chronic kidney disease and Type 2 diabetes since these patients face significant risk of cardiovascular disease and death. Cardiovascular events like heart attacks, heart failure and stroke are some of the leading causes of death in this patient group.

After follow-up of more than 2-1/2 years, researchers found a daily, oral treatment at 10 mg or 20 mg with finerenone reduced by 14% the risk of cardiovascular events for patients who already had a history of heart disease and for those who had no previous history. It also reduced the rate of death, heart attack, stroke and hospitalization for heart failure among patients with chronic kidney disease and Type 2 diabetes.
-end-
There are additional phase III trials of finerenone in progress.

Co-authors are Stefan D. Anker, M.D.; Rajiv Agarwal, M.D., M.S.; Bertram Pitt, M.D.; Peter Rossing, M.D.; Luis M. Ruilope, M.D.; Peter Kolkhof, Ph.D.; Patrick Schloemer, Ph.D.; Amer Joseph, M.B.B.S.; Ingo Tornus, Ph.D.; and George L. Bakris, M.D. Author disclosures are in the abstract. The study was funded by Bayer AG.

Presentation: LBS.07 - Randomized Trials - Brain, Kidney, and Heart

Additional Resources:

Multimedia is available on the right column of the release link https://newsroom.heart.org/news/new-medication-helps-heart-health-in-people-with-chronic-kidney-disease-type-2-diabetes?preview=e7ff33b3a00018838af1129f184ed152

Why Diabetes Matters
Kidney disease and diabetes
For more news at AHA Scientific Sessions 2020, follow us on Twitter @HeartNews

Statements and conclusions of studies that are presented at the American Heart Association's scientific meetings are solely those of the study authors and do not necessarily reflect the Association's policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and biotech companies, device manufacturers and health insurance providers are available here, and the Association's overall financial information is available here.

About the American Heart Association

The American Heart Association is a leading force for a world of longer, healthier lives. With nearly a century of lifesaving work, the Dallas-based association is dedicated to ensuring equitable health for all. We are a trustworthy source empowering people to improve their heart health, brain health and well-being. We collaborate with numerous organizations and millions of volunteers to fund innovative research, advocate for stronger public health policies, and share lifesaving resources and information. Connect with us on heart.org, Facebook, Twitter or by calling 1-800-AHA-USA1.

American Heart Association

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.